Isolated familial somatotropinomas : Establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12

• Published in: The journal of clinical endocrinology and metabolism 2000-02, Vol.85 (2), p.707-714
• Main Authors: GADELHA, M. R, UNE, K. N, ROHDE, K, VAISMAN, M, KINEMAN, R. D, FROHMAN, L. A
• Format: Article
• Language: English
• Subjects: Acromegaly - genetics; Adolescent; Adult; Biological and medical sciences; Chromosome Mapping; Chromosomes, Human, Pair 11 - genetics; Chromosomes, Human, Pair 17 - genetics; Chromosomes, Human, Pair 2 - genetics; Endocrinopathies; Female; Genetic Linkage; Gigantism - genetics; Haplotypes; Humans; Hypothalamus. Hypophysis. Epiphysis (diseases); Lod Score; Male; Medical sciences; Non tumoral diseases. Target tissue resistance. Benign neoplasms; Pedigree
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.85.2.707

The majority of somatotropinomas are sporadic, although a small number occur with a familial aggregation, either as a component of an endocrine neoplasia complex that includes multiple endocrine neoplasia type 1 (MEN-1) and Carney complex (CNC) or as isolated familial somatotropinomas (IFS). IFS is defined as the occurrence of at least two cases of acromegaly or gigantism in a family that does not exhibit MEN-1 or CNC. This rare disease is associated with loss of heterozygosity (LOH) on chromosome 11q13, the locus of the MEN-1 gene, although the MEN-1 sequence and expression appear normal. These data suggest the presence of another tumor suppressor gene located at 11q13 that is important in the control of somatotrope proliferation. To establish linkage of IFS to 11q13 and to define the candidate interval of the IFS gene, we performed haplotype and allelotype analyses on two families with IFS. Collectively, allelic retention in one tumor and a recombinant haplotype in an affected individual mapped the tumor suppressor gene involved in the pathogenesis of IFS to a region of 8.6 cM between polymorphic microsatellite markers D11S1335 and INT-2 located at chromosome 11q13.1-13.3. Maximum two-point LOD scores for five markers within this region were 3.0 or more at theta = 0.0. As somatotropinomas are the predominant pituitary tumor subtype associated with CNC and arise before 30 yr of age, which is strikingly similar to the age at diagnosis for IFS, we explored the possibility that the putative CNC genes might also contribute to the pathogenesis of IFS. Although the genetic defect responsible for the complex is unknown, CNC has been mapped by linkage analysis to chromosomes 2p15-16 and 17q23-24 in different kindreds. Two-point LOD scores less than -2.0 were obtained using marker D17S949 from chromosome 17q23-24, excluding linkage. However, LOD scores of 2.5 were obtained for markers within 2p16-12; therefore, linkage of IFS to chromosome 2p cannot be excluded. This report establishes linkage of the tumor suppressor gene involved in the pathogenesis of IFS to chromosome 11q13.1-13.3 and identifies a potential second locus at chromosome 2p16-12.